RxDoctor Payments Data

David Whitney, MD

Neurology · Fairfax, VANPI 1699113175

Payments from drug & device makers

$12,381in general payments, 2019–2025

Across 331 payments — averaging $37.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Abbott$2K
  • Boston Scientific$1K
  • MDD US Operations, LLC$924
  • Neurocrine Biosciences, Inc.$505
  • Supernus Pharmaceuticals, Inc.$481
  • plus $5K from 38 others

What the payments were for

  • Speaking & faculty fees$480%
  • Travel & lodging$1,37511%
  • Food & beverage$10,94488%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,381 in reported general payments places this provider in the 70th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$259,375
Medicare patients
574
Services billed
14,953

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa190$261,965
NuplazidPimavanserin Tartrate40$231,267
IngrezzaValbenazine Tosylate19$155,356
Austedo XrDeutetrabenazine14$139,737
GocovriAmantadine Hcl33$82,265
InbrijaLevodopa20$49,534
NeuproRotigotine24$33,817
Carbidopa-LevodopaCarbidopa/Levodopa963$24,637
Rasagiline Mesylate116$20,473
Pramipexole ErPramipexole Di-Hcl26$12,154
Primidone321$8,799
Entacapone20$8,511
Propranolol Hcl ErPropranolol Hcl167$7,370
Carbidopa-Levodopa ErCarbidopa/Levodopa186$5,889
Gabapentin293$5,181

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$98$261,965190 claims
Acadia Pharmaceuticals IncNuplazid$47$231,26740 claims
Neurocrine Biosciences, Inc.Ingrezza$505$155,35619 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$216$139,73714 claims
MDD US Operations, LLCGocovri$924$82,26533 claims
Acorda Therapeutics, IncInbrija$64$49,53420 claims
UCB, Inc.Neupro$431$33,81724 claims
Upsher-smith Laboratories LLCTopiramate$28$66128 claims
Almatica Pharma LLCSertraline Hcl$68$60359 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 474 neurology providers in Virginia.

Other neurology in Fairfax

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →